Stock analysis · Bull Rankings model

USPH analysis

U.S. Physical Therapy, Inc.Medical Care Facilities. Scored on the same transparent 7-signal model behind the daily rankings.

USPH
U.S. Physical Therapy, Inc. · Medical Care Facilities
1Y-12%C
Rev+16.3%B+
ROE7.4%C+
FCF$67mC-
73Score
$66.39
1Y Target$93.67Near-term target
5Y Target$137.14Compound horizon
10Y Target$203.43Long-dated conviction
1Y-12%
C
-12% over 12 months — flat-to-soft
Rev+16.3%
B+
Revenue +16.3% — above sector median, healthy trajectory
ROE7.4%
C+
ROE 7.4% — subdued returns on equity
FCF$67m
C-
FCF $67m — barely positive; fragile cash position
Entry · Margin of safety
52-week rangeNear 52-week low
29% off the 12-month high
vs DCF fair value36% belowest. fair value ~$85
Quality signals · context only
ROIC9.3% · Breturn on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $1.0b. Down 29% from 52-week high of $93.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 6 sell-side analysts publish a mean 1-yr target of $93.67 (implying +41% upside).
Moat
FCF converts 192% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 132.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Net margin 4.4% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $93.67 (6-analyst consensus) — fundamentals + valuation re-rating. 5 yr $137.14 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $203.43 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Shares to buy
30
Position size
$1,992
4.0% of portfolio
Stop price
$49.79
25% below $66.39
$ at risk if stopped
$497.93
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

U.S. Physical Therapy, Inc. (USPH): score, valuation & FAQ

U.S. Physical Therapy, Inc. (USPH) is a Medical Care Facilities company that scores 73 out of 110 on the Bull Rankings fundamentals model — a solid, above-average reading. The score is a transparent, rules-based read of the company's published fundamentals, refreshed daily; it is a screen, not a buy recommendation.

Its strongest graded signals are Rev (B+), while FCF (C-) rate weaker. On valuation, USPH implies roughly +36% upside versus our discounted-cash-flow fair value.

Is USPH a good stock to buy?

Bull Rankings scores USPH 73 out of 110 in its fundamentals bucket, which is a solid, above-average reading. That is driven by Rev (B+). A score is a quantitative screen of U.S. Physical Therapy, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does USPH score 73 on Bull Rankings?

The score is a bucket-weighted blend of fundamental signals — free cash flow, revenue growth, leverage, valuation, and quality. USPH earns its highest marks on Rev (B+), and is held back by FCF (C-). Each signal is graded against sector-aware thresholds, then combined into the 0–110 composite.

Is USPH overvalued or undervalued?

Based on $66.39, USPH implies roughly +36% upside versus our discounted-cash-flow fair value. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.

What are the main risks of investing in USPH?

Trailing P/E 132.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Net margin 4.4% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.

Analyze another ticker →